FY2024 EPS Estimates for Glaukos Raised by Zacks Research

Glaukos Co. (NYSE:GKOS) – Research analysts at Zacks Research boosted their FY2024 earnings per share estimates for shares of Glaukos in a research note issued on Monday, November 25th. Zacks Research analyst I. Bandyopadhyay now forecasts that the medical instruments supplier will post earnings of ($1.98) per share for the year, up from their previous estimate of ($2.32). The consensus estimate for Glaukos’ current full-year earnings is ($1.96) per share. Zacks Research also issued estimates for Glaukos’ Q4 2024 earnings at ($0.48) EPS, Q1 2025 earnings at ($0.36) EPS, Q2 2025 earnings at ($0.29) EPS, Q3 2025 earnings at ($0.31) EPS, Q4 2025 earnings at ($0.25) EPS, FY2025 earnings at ($1.22) EPS, Q1 2026 earnings at ($0.20) EPS, Q2 2026 earnings at ($0.02) EPS, Q3 2026 earnings at ($0.04) EPS and FY2026 earnings at ($0.23) EPS.

Other research analysts have also issued reports about the company. Needham & Company LLC boosted their price target on shares of Glaukos from $131.00 to $137.00 and gave the stock a “buy” rating in a research report on Thursday, August 1st. Stifel Nicolaus boosted their target price on shares of Glaukos from $130.00 to $145.00 and gave the stock a “buy” rating in a report on Tuesday, September 3rd. Truist Financial lifted their price target on shares of Glaukos from $145.00 to $152.00 and gave the stock a “buy” rating in a research report on Monday, October 14th. Wells Fargo & Company raised their price objective on Glaukos from $135.00 to $145.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 5th. Finally, Piper Sandler set a $140.00 target price on Glaukos in a report on Thursday, October 17th. Four research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $135.45.

Glaukos Stock Performance

Shares of GKOS stock opened at $142.69 on Thursday. The stock has a market capitalization of $7.87 billion, a price-to-earnings ratio of -47.25 and a beta of 1.02. The company’s 50-day simple moving average is $133.56 and its 200-day simple moving average is $124.39. The company has a debt-to-equity ratio of 0.19, a quick ratio of 4.71 and a current ratio of 5.54. Glaukos has a one year low of $59.58 and a one year high of $146.86.

Glaukos (NYSE:GKOS) last released its quarterly earnings results on Monday, November 4th. The medical instruments supplier reported ($0.28) EPS for the quarter, topping the consensus estimate of ($0.48) by $0.20. Glaukos had a negative return on equity of 18.99% and a negative net margin of 42.43%. The business had revenue of $96.70 million for the quarter, compared to analysts’ expectations of $91.50 million. During the same quarter in the previous year, the firm posted ($0.50) earnings per share. The company’s revenue was up 23.9% compared to the same quarter last year.

Hedge Funds Weigh In On Glaukos

A number of institutional investors have recently made changes to their positions in GKOS. Values First Advisors Inc. acquired a new position in Glaukos during the 3rd quarter valued at $25,000. Harvest Fund Management Co. Ltd raised its holdings in Glaukos by 2,263.2% in the 3rd quarter. Harvest Fund Management Co. Ltd now owns 898 shares of the medical instruments supplier’s stock valued at $117,000 after acquiring an additional 860 shares in the last quarter. GAMMA Investing LLC grew its holdings in shares of Glaukos by 68.8% during the 2nd quarter. GAMMA Investing LLC now owns 1,192 shares of the medical instruments supplier’s stock worth $141,000 after purchasing an additional 486 shares in the last quarter. Fifth Third Wealth Advisors LLC acquired a new stake in shares of Glaukos during the 2nd quarter worth approximately $187,000. Finally, KBC Group NV increased its position in shares of Glaukos by 16.2% during the third quarter. KBC Group NV now owns 1,445 shares of the medical instruments supplier’s stock valued at $188,000 after purchasing an additional 201 shares during the period. 99.04% of the stock is currently owned by institutional investors.

Insider Activity

In other Glaukos news, COO Joseph E. Gilliam sold 2,275 shares of the firm’s stock in a transaction dated Wednesday, October 30th. The stock was sold at an average price of $138.97, for a total transaction of $316,156.75. Following the transaction, the chief operating officer now directly owns 102,169 shares in the company, valued at $14,198,425.93. This trade represents a 2.18 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Gilbert H. Kliman sold 3,000 shares of the firm’s stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $130.67, for a total value of $392,010.00. Following the completion of the transaction, the director now directly owns 32,336 shares in the company, valued at $4,225,345.12. The trade was a 8.49 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 6.40% of the stock is currently owned by corporate insiders.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.